Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Senzime AB (publ) (SEZI.ST)
Uppsala, SE
Senzime AB (publ) is a medical technology firm specializing in the creation and distribution of advanced patient monitoring solutions. These systems are designed to oversee patients undergoing anesthesia across various global markets, including Europe, Oceania, Asia, Canada, and the United States. Among its primary offerings is the TetraGraph, a sophisticated monitor designed to assess and display muscle function in surgical patients administered neuromuscular blocking agents, by stimulating, measuring, and analyzing responses. This system is complemented by the TetraSens electrode array, featuring two proximal stimulating electrodes for precise recording and reference. For data management, TetraConnect serves as a portal, allowing clinicians to conveniently access, view, and export TetraGraph data records in PDF or Excel formats. Furthermore, TetraGraph Device Connectivity facilitates the transfer of data from the TetraGraph Monitor to other patient monitoring systems, while the TetraGraph Philips Interface specifically enables the transmission of critical neuromuscular monitoring parameters—such as TOFC, TOFR, PTC, and TOF bars—to Philips patient monitors, with readings visible on the Philips Intellivue Monitor. Senzime is also actively developing the CliniSenz Analyzer, intended for continuous postoperative patient monitoring within hospital settings. Another innovation in its pipeline is the Onzurf Probe, a sterile, CE-marked single-use device leveraging micro-dialysis technology for continuous sampling from gastrointestinal organs, including the esophagus, stomach, and liver. The company maintains a strategic licensing and connectivity partnership with Masimo. This collaboration focuses on developing and commercializing the TetraGraph Smart Cable Module, designed to integrate seamlessly with Masimo's Root monitoring system and their digital hubs, thereby enabling interaction with hospital clinical information systems and electronic health records. Established in 1999, Senzime AB (publ) operates from its headquarters in Uppsala, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +9.25% | +7.13% | +4.64% | +10.22% | -7.12% | -8.49% | +6.21% | +11.21% | -78.98% | -15.75% | -25.74% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+77.9% ★ Q1'26: -1.1% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+4.1% Q1'26: +46.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-122.1% Q1'26: -111.2% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-116.3% Q1'26: -97.3% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-49.5% Q1'26: -35.0% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+20.2% Q1'26: +18.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.15× Q1'26: -0.32× (vs Q1'25)
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
152.6K
est: 600.0K (-74.6%)
|
1.63M
est: 2.00M (-18.6%)
|
189.0K
est: 176.0K (+7.4%)
|
3.21M
est: 4.37M (-26.4%)
|
6.71M
est: 10.00M (-32.9%)
|
9.34M
est: 8.90M (+4.9%)
|
10.98M
est: 10.00M (+9.8%)
|
14.03M
est: 27.60M (-49.2%)
|
35.75M
est: 47.04M (-24.0%)
|
58.48M
est: 62.00M (-5.7%)
|
104.02M
est: 103.80M (+0.2%)
|
152.70M
152.70M – 152.70M
+47.1% YoY
|
232.30M
232.30M – 232.30M
+52.1% YoY
|
330.60M
330.60M – 330.60M
+42.3% YoY
|
| EBITDA |
-6.33M
est: -600.0K (-954.5%)
|
-8.73M
est: -2.00M (-336.7%)
|
-12.67M
est: -176.0K (-7,098.9%)
|
-21.27M
est: -4.37M (-386.8%)
|
-23.04M
est: -10.00M (-130.4%)
|
-36.96M
est: -8.90M (-315.3%)
|
-73.21M
est: -10.00M (-632.1%)
|
-120.05M
est: -27.60M (-334.9%)
|
-118.82M
est: -46.37M (-156.3%)
|
-95.53M
est: -61.11M (-56.3%)
|
-96.59M
est: -102.32M (+5.6%)
|
-150.52M
-150.52M – -150.52M
-47.1% YoY
|
-228.98M
-228.98M – -228.98M
-52.1% YoY
|
-325.87M
-325.87M – -325.87M
-42.3% YoY
|
| EBIT |
-7.58M
est: -600.0K (-1,163.3%)
|
-9.41M
est: -2.00M (-370.6%)
|
-13.03M
est: -176.0K (-7,300.6%)
|
-24.54M
est: -4.37M (-461.8%)
|
-34.23M
est: -10.00M (-242.3%)
|
-48.87M
est: -8.90M (-449.1%)
|
-84.21M
est: -10.00M (-742.1%)
|
-133.93M
est: -27.60M (-385.2%)
|
-136.36M
est: -47.04M (-189.9%)
|
-121.75M
est: -62.00M (-96.4%)
|
-120.98M
est: -103.80M (-16.6%)
|
-152.70M
-152.70M – -152.70M
-47.1% YoY
|
-232.30M
-232.30M – -232.30M
-52.1% YoY
|
-330.60M
-330.60M – -330.60M
-42.3% YoY
|
| Net Income |
-7.58M
est: -63.92M (+88.1%)
|
-9.41M
est: -28.41M (+66.9%)
|
-13.03M
est: -42.81M (+69.6%)
|
-25.62M
est: -40.65M (+37.0%)
|
-33.68M
est: -74.20M (+54.6%)
|
-47.45M
est: -63.94M (+25.8%)
|
-82.14M
est: -145.98M (+43.7%)
|
-132.70M
est: -167.69M (+20.9%)
|
-134.15M
est: -169.16M (+20.7%)
|
-118.73M
est: -132.36M (+10.3%)
|
-137.42M
est: -102.95M (-33.5%)
|
-29.41M
-29.41M – -29.41M
+71.4% YoY
|
79.42M
79.42M – 79.42M
+370.0% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
3.55M
est: 2.80M (+26.7%)
|
6.51M
est: 9.33M (-30.2%)
|
7.56M
est: 820.8K (+820.4%)
|
10.32M
est: 20.38M (-49.4%)
|
14.53M
est: 46.64M (-68.9%)
|
31.14M
est: 41.51M (-25.0%)
|
67.71M
est: 46.64M (+45.2%)
|
114.39M
est: 128.72M (-11.1%)
|
122.79M
est: 199.70M (-38.5%)
|
130.53M
est: 263.21M (-50.4%)
|
129.32M
est: 440.66M (-70.7%)
|
648.26M
648.26M – 648.26M
+47.1% YoY
|
986.19M
986.19M – 986.19M
+52.1% YoY
|
1.40B
1.40B – 1.40B
+42.3% YoY
|
| EPS |
-0.49
est: -0.52 (+6.2%)
|
-0.33
est: -0.23 (-42.1%)
|
-0.33
est: -0.35 (+5.7%)
|
-0.59
est: -0.33 (-77.5%)
|
-0.66
est: -0.61 (-8.8%)
|
-0.83
est: -0.52 (-58.8%)
|
-1.30
est: -1.19 (-8.9%)
|
-1.96
est: -1.37 (-43.0%)
|
-1.45
est: -1.15 (-26.1%)
|
-0.97
est: -0.90 (-7.8%)
|
-0.93
est: -0.70 (-32.9%)
|
-0.20
-0.20 – -0.20
+71.4% YoY
|
0.54
0.54 – 0.54
+370.0% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap ETF DFIS | 0.00% | 23.8K | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Philip Siberg | Chief Executive Officer | 5M | male |
| Catrin Molund | Executive Vice President of Business Development | 163.0K | female |
| Johanna Faris | Head of Q/RA/S | — | female |
| Johanna Tulkki | Executive Vice President & Chief Operating Officer | — | female |
| Michael Noble | Chief Marketing Officer | — | male |
| Paula Treutiger | Head of Communication & Investor Relations | — | female |
| Anders Jacobson | Chief Scientific Officer | — | male |
| Slavoljub Grujicic | Chief Financial Officer | — | male |
| G.W Hamilton | President of Senzime Inc | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SEZI.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
